Azitra closed at $0.82 on Nov 4, down 7.71%, 83.4% below its 52-week closing high. Volume of 136.8K shares was 0.02× its 20-day average (below normal).
Split-adjusted performance: -37.3% over one month, -66.7% over six months.
Short interest was 112.3K shares at the Oct 15 settlement, down 53.4% from the prior report (0.2% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| AZTRAzitra | $0.8157 | −7.71% | −66.7% | — | — | — | $4.9M | |
| SKYESkye Bioscience | $1.14 | −6.56% | −83.3% | — | — | — | $5.0M | Compare |
| IMNNImunon | $0.9070 | +0.78% | −66.5% | — | — | — | $5.1M | Compare |
| XBIOXenetic Biosciences | $2.01 | −3.37% | −36.6% | +12.0% | −140.7% | — | $4.7M | Compare |
| TCRTAlaunos Therapeutics | $1.80 | −3.23% | −31.6% | — | — | — | $4.6M | Compare |
| PCSAProcessa Pharmaceuticals | $1.94 | −0.26% | −29.6% | — | — | — | $5.4M | Compare |
| APUSApimeds Pharmaceuticals US | $2.92 | −1.68% | −85.0% | — | — | — | $4.4M | Compare |
| PULMPulmatrix | $1.52 | +14.29% | +11.8% | — | — | — | $5.6M | Compare |
| SCNXScienture Holdings | $3.42 | −0.87% | −65.0% | — | −821.3% | — | $5.6M | Compare |
No recent articles focused on Azitra.
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
